A group of pharmaceutical executives left.

On June 12, Fu'an Pharmaceuticals announced that its company's board of directors received a written resignation report from Jiang Chen, the company's director and general manager, who applied for his resignation as a director, a member of the board's strategy committee and a general manager for personal reasons. After
resign, Jiang Chen will not hold other positions at Fu'an Pharmaceuticals.
Jiang Chen's original term of office expires on December 20, 2021.
until the new general manager comes to office, the chairman wang Tianxiang is temporarily replaced by the general manager to perform the duties.
Fuan Pharmaceuticals will complete the by-election of directors and the appointment of a general manager as soon as possible.
Tianjin Lisheng Pharmaceuticals on June 11, Tianjin Lisheng Pharmaceuticals issued a notice that, after verification, Qi Tie-hye due to changes in work reasons no longer serve as directors, chairman of the board, the strategic and development committee of the position of the same reasons.
Qi Tiewill will no longer hold any position in the company.
On June 10, Ha Pharmaceuticals agnd shares announced that the board of directors received the resignation of Gao Lei, the company's deputy general manager, for personal reasons Gao Lei resigned as the company's deputy general manager, resigned from the company after the appointment of no other position in the company. according to
, Gao Lei's term as deputy general manager ends on October 25, 2020. As of March 31, 2020, four vice-presidents of Liu Gangmin, Wu Zhijun, Zhou Xing and Wei Shuangying have left their posts, with the exception of Wu Zhijun, all of whom left for "personal reasons," according to the 2019 annual report of
.S.
Mingde Bio June 5, Wuhan Mingde Bio issued a notice that recently received the company's deputy general manager, the secretary of the board of directors Zhou Yun written resignation report, Zhou Yun for personal reasons to apply to resign from the company's deputy general manager, the board secretary, his resignation report from the date of service to the board of directors.
Zhou Yun will no longer hold any position in Minder Bio after he resigns as deputy general manager and secretary of the board of directors.
During the company's non-formal appointment of a new secretary to the board of directors, the board of directors of the company appointed wang Rui, the deputy general manager of the company, to act as secretary of the board of directors, and the company will appoint a new secretary of the board of directors as soon as possible in accordance with the relevant provisions.
Tianrui Pharmaceuticals On June 3, Guilin Tianrui Pharmaceuticals issued two announcements announcing the resignation of Zhong Ming, general manager of the company, and Zhao Guifang, director and supervisor.
announcement, Zhong Ming, Zhao Guifang for personal reasons to resign from the above positions. After
resigned, Zhong Ming continued as chairman and Zhao Guifang continued as supervisor.
China's pharmaceutical and health industry On June 1, China Pharmaceutical and Health Industry Co., Ltd. announced that it had recently received a written resignation report from director and general manager Hou Wenling.
due to job adjustment reasons, Hou Wenling applied to resign from the company's director, general manager and board of directors of the relevant positions, and will no longer hold any positions in the company.
Fosun Pharma on June 1, Fosun Pharma announced that the board of directors received a written resignation letter from Li Jianqing.
for personal reasons, Li Jianqing applied to the company's board of directors to resign as vice president, and as of May 31, 2020, Li Jianqing will no longer serve as vice president of the company.
According to Fosun Pharma's 2019 annual report, Li Jianqing was promoted to vice president on January 21 this year, holding about 235,000 shares of Fosun Pharma, with an annual salary of 1.8989 million yuan.
, fosun Pharma has resigned three vice-presidents so far this year. On April 17,
, Dai Kun, foer's vice president, resigned for personal reasons, and on May 6, Fosun Pharma announced that Hequn Yin, the company's senior vice president, had resigned.
Lizhu Pharmaceuticals on May 29, Lizhu Pharmaceuticals announced that Dai Weiguo voluntarily resigned as Vice President of the Company and all positions held by subsidiaries for personal family and development reasons.
it is understood that Dai Weiguo joined Lizhu Pharmaceutical Group on April 11, 2019, replacing Fu Daotian as general manager of Zhuhai Lizhu Singanti-Biotech Co., Ltd.
East Agu May 22, Dong'a gum announced that its vice president Zhou Xiangshan due to job changes to resign his position as vice president of the company.
Fourth Ring Biology on May 22, Four Rings Bio night notice said that Sun Guojian for personal reasons to apply to resign the chairman, director, board of directors of the relevant positions and general manager of the special committee. After
resigned, Sun Guojian no longer held any position in the company.
it is understood that the four-ring biological has been punished by the Csrc, the actual controller was fined 27.34 million.
Haixiang Pharmaceuticals on May 16, Zhejiang Haixiang Pharmaceuticals issued a notice that the company's board of directors recently received a written resignation report from director and general manager Yang Siwei.
Yang Siwei applied to resign his position as a director and general manager of the company for personal reasons.
Yang Siwei resigns from any position in the company and its subsidiaries.
as of the date of disclosure of this announcement, Yang Siwei holds 4.8578 million shares of the Company, and his shares will be managed in strict accordance with relevant laws, regulations and related commitments.
multiple factors, the pressure on the pharmaceutical industry has intensified According to The seiber blue incomplete statistics, in January-March this year, the industry has more than 60 executives have left.
April, 18 pharmaceutical executives filed for departure, bringing the number of executives at the president's level alone to 13.
the reasons for these executives' resignation mainly include work reasons, personal reasons, term of office, division of work adjustment, etc. , which mainly for personal reasons.
there are a number of pharmaceutical companies in a short period of time, a number of executives left, such as Huaren Pharmaceuticals, Northeast Pharmaceuticals, Kazakhstan Pharmaceuticals, Fosun Pharmaceuticals and so on.
since the spread of the new crown epidemic in China, many pharmaceutical enterprises have been affected by the epidemic obviously.
, according to Minnet.com, more than 50% of A-share pharmaceutical companies in the first quarter of this year's operating income and net profit fell, with 53 pharmaceutical companies losing net profit, compared with 16 in the same period last year.
as of June 5, a total of 39 pharmaceutical companies disclosed first-half results, less than half of the pharmaceutical companies are happy.
during the new crown outbreak, most hospitals in the country were affected to varying degrees, many hospitals closed some outpatient departments, reduce the admission of inpatients, many ordinary patients in order to reduce the risk of infection, cancel or postpone hospital visits, resulting in hospital outpatient volume, inpatient volume during the outbreak decline, many pharmaceutical companies production, logistics and distribution, marketing work is affected by production and operation.
in addition to sudden factors, in the long run, the pharmaceutical industry costs rise, profit margin compression, and then superimposed 4 plus 7 belt procurement, two-vote system, tender price reduction, medical insurance fees and consistency evaluation and other national new round of medical reform policy, the pharmaceutical industry or will be under long-term pressure.
under the challenge, pharmaceutical companies to adjust management, change personnel system, optimize the business team, pharmaceutical personnel to find new career development opportunities are high probability events.
.